Pyxis Oncology
PYXS
Market cap $192M

3.23 USD

+0.07

2.22%

At close Oct 11, 4:00 PM EDT

After hours

3.09

-0.14

4.33%

1 day

2.22%

5 days

-7.71%

1 month

-11.26%

3 months

8.75%

6 months

-38.71%

Year to date

56.80%

1 year

57.56%

5 years

-75.53%

About: Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.

Employees: 55

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

9,133% more call options, than puts

Call options by funds: $1.66M | Put options by funds: $18K

56% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 16

13% more funds holding

Funds holding: 71 [Q1] → 80 (+9) [Q2]

8.25% more ownership

Funds ownership: 39.52% [Q1] → 47.77% (+8.25%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

5% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 21

5% less capital invested

Capital invested by funds: $97.9M [Q1] → $93.1M (-$4.78M) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$7

117%

upside

Avg. target

$8

148%

upside

High target

$10

210%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

RBC Capital Leonid Timashev 60% 1-year accuracy 21 / 35 met price target	117%upside $7	Outperform Reiterated	19 Sept 2024
HC Wainwright & Co. Swayampakula Ramakanth 25% 1-year accuracy 32 / 130 met price target	117%upside $7	Buy Reiterated	16 Aug 2024
Stifel Bradley Canino 35% 1-year accuracy 11 / 31 met price target	210%upside $10	Buy Initiated	8 Aug 2024

See Analyst Rankings

Financial journalist opinion

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS)

NEW YORK , Sept. 25, 2024 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Pyxis Oncology, Inc. (NASDAQ:PYXS) concerning possible breaches of fiduciary duty.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS)

Moment Of Truth Approaches For Pyxis Oncology

Pyxis Oncology is an antibody and antibody-drug conjugate developer with initial results from two clinical trials ahead in 2024. Data from a phase 1 study of PYX-201, an ADC targeting extra domain B of fibronectin, in multiple tumor types, are expected in fall 2024. Data from a phase 1 study of PYX-106, an anti-Siglec-15 antibody, in multiple tumor types, are expected by year-end 2024.

Moment Of Truth Approaches For Pyxis Oncology

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in fireside chats and members of management will participate in one-on-one meetings at the following two upcoming investor conferences:

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024

- Preliminary data from the Phase 1 trial of PYX-201 remains on track to be announced in the fall of 2024 - Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 - Expected cash runway into 2H 2026 BOSTON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. The Company ended the second quarter of 2024 with $157.2 million in cash, cash equivalents, restricted cash and short-term investments, which is expected to provide cash runway into the second half of 2026 and enable the Company to fund the next phase of PYX-201 clinical development, which the Company plans to announce in the fall of 2024.

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024

Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference

BOSTON, July 29, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, and members of management will participate in one-on-one meetings at the BTIG Virtual Biotechnology Conference being held August 5-6, 2024.

Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, reported today that Pyxis Oncology's Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 89,530 shares of Pyxis Oncology's common stock and stock options to purchase an aggregate of 111,913 shares of Pyxis Oncology's common stock to five newly hired employees. The awards were granted under the Pyxis Oncology, Inc. 2022 Inducement Plan with a grant date of June 28, 2024, as an inducement material to the new employee entering employment with Pyxis Oncology, in accordance with Nasdaq Listing Rule 5635(c)(4).

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) since 2015.

Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger

Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Thursday, June 6, 2024 at 9:00 AM Eastern Time at the Jefferies Global Healthcare Conference in New York City, where members of management will also host investor one-on-one meetings.

Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

Zacks Investment Research

Pyxis Oncology, Inc. (PYXS) Reports Q1 Loss, Tops Revenue Estimates

Pyxis Oncology, Inc. (PYXS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.54 per share a year ago.

Pyxis Oncology, Inc. (PYXS) Reports Q1 Loss, Tops Revenue Estimates

Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of Stephen Worsley as Senior Vice President, Chief Business Officer PYX-106 Phase 1 trial clinical readout on track for 2H 2024 Expected cash runway into 2H 2026 BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. PYX-201, a first-in-concept tumor stroma targeting antibody-drug conjugate (ADC) against the stromal Extradomain-B Fibronectin (EDB+FN) target, has dosed 42 patients in 8 cohorts since initiating the Phase 1 trial in March 2023 with continued enthusiasm for this agent by global investigators.

Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

See News Rankings

Charts implemented using Lightweight Charts™